Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation

Academic Article

Abstract

  • Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up. Copyright © 2001 International Society for Heart and Lung Transplantation.
  • Digital Object Identifier (doi)

    Pubmed Id

  • 23174959
  • Author List

  • Zilz ND; Olson LJ; McGregor CG
  • Start Page

  • 770
  • End Page

  • 772
  • Volume

  • 20
  • Issue

  • 7